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Background: A major obstacle in the use of retinoid therapy in cancer is the resistance to this agent in tumors.
Retinoic acid facilitates the growth of mammary carcinoma cells which express high levels of fatty acid-binding protein
5 (FABP5). This protein delivers retinoic acid to peroxisome proliferator-activated receptor β/δ (PPARβ/δ) that targets
genes involved in cell proliferation and survival. One approach to overcome resistance of mammary carcinoma cells to
retinoic acid is to target and suppress the FABP5/ PPARβ/δ pathway. The objective of this research was to investigate
the effect of curcumin, a polyphenol extract from the plant Curcuma longa, on the FABP5/ PPARβ/δ pathway in
retinoic acid resistant triple negative breast cancer cells.
Methods: Cell viability and proliferation of triple negative breast cancer cell lines (MDA-MB-231 and MD-MB-468)
treated with curcumin and/or retinoic was analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) and 5-bromo-2’-deoxyuridine (BrdU). Expression level of FABP5 and PPARβ/δ in these cells treated with curcumin
was examined by Western Blotting analysis and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Effect of
curcumin and retinoic acid on PPARβ/δ target genes, PDK1and VEGF-A were also examined using qRT-PCR. Western
Blotting was utilized to examine the protein expression level of the p65 subunit of NF-κB.
Results: Treatment of retinoic acid resistant triple negative breast cancer cells with curcumin sensitized these cells to
retinoic acid mediated growth suppression, as well as suppressed incorporation of BrdU. Further studies demonstrated
that curcumin showed a marked reduction in the expression level of FABP5 and PPARβ/δ. We provide evidence that
curcumin suppresses p65, a transcription factor known to regulate FABP5. The combination of curcumin with retinoic
acid suppressed PPARβ/δ target genes, VEGF-A and PDK1.
Conclusions: Curcumin suppresses the expression level of FABP5 and PPARβ/δ in triple negative mammary carcinoma
cells. By targeting the FABP5/PPARβ/δ pathway, curcumin prevents the delivery of retinoic acid to PPARβ/δ and
suppresses retinoic acid-induced PPARβ/δ target gene, VEGF-A. Our data demonstrates that suppression of the FABP5/
PPARβ/δ pathway by curcumin sensitizes retinoic acid resistant triple negative breast cancer cells to retinoic acid
mediated growth suppression.
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proliferator-activated receptor β/δBackground
Although breast cancer is the second most leading cause
of death among women in the western world, early
detection and new treatments have improved survival
rates [1]. However, no effective treatment for metastatic,
triple negative breast cancer (TNBC) is available following
surgery, radiation and chemotherapy for the primary* Correspondence: pthulasiraman@southalabama.edu
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15-20% of all breast cancers and the signature of
TNBCs is the lack of the estrogen receptor, progester-
one receptor and the lack of the overexpression of
HER2 [4,5]. Drug resistance is a major problem in
TNBC patients, promoting the need to understand the
molecular mechanisms involved in the disease and
identify future targeted therapy. Several promising
agents are currently under clinical trials for the preventionentral Ltd. This is an Open Access article distributed under the terms of the
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inhibitors, vitamin D and rexinoids [6].
Anticancer drugs, derived from natural sources, have
been used alone or in combination with traditional drugs
to treat multiple diseases, including cancer [7-9]. Curcu-
min derived from the plant Curcuma longa has been
used as a dietary agent, food preservative and a longtime
favorite Asian medicinal treatment [10]. It is a hydropho-
bic polyphenol derived from turmeric (Curcuma longa)
that has anti-oxidant, anti-inflammatory and anti-
cancer properties, promoting its potential for targeting
various diseases, including cancer, arthritis, athero-
sclerosis, diabetes, and auto-immune diseases [11,12].
Curcumin has exhibited inhibitory effects on several
malignant cancers, including breast cancer [13-16]. It
has been used in clinical trials for colorectal cancer
[17] and pancreatic cancer [18], and its use in combin-
ation with other therapeutic drugs promotes the sup-
pression of tumor growth [19-21]. Due to the low
bioavailability and high metabolic instability of curcu-
min, development of analogs of curcumin and nanocurcu-
min to improve their chemotherapeutic efficacies are
being investigated as next generation targeted therapy
[22,23]. Despite its current limitations, curcumin is
highlighted for its efficacy in chemoprevention and
reversing chemo-resistance in certain tumors [24-26].
The ability of curcumin and its analogs to enhance the
efficacy of existing chemotherapeutic agents will add
value for its use in the treatment of highly aggressive
chemo-resistant breast tumors.
The effect of curcumin is in part due to its ability to
interfere with multiple signaling cascades such as cell
cycle regulators, apoptotic proteins, pro-inflammatory
cytokines, proliferative regulators and transcription fac-
tors such as nuclear factor-kappa B (NF-κB) and Stat3
[27]. It inhibits cancer cell and tumor growth, suppresses
proliferation, and blocks angiogenesis and inflammation.
Due to its pleiotropic effect, the role of curcumin to
regulate various signaling pathways and genes have been
reported in different cancer cell lines [28].
The use of retinoid therapy in cancer is promoted by
the ability of retinoids to induce differentiation, cell cycle
cycle arrest and apoptosis [29,30]. Due to its favorable
effect on the treatment of acute promyelocytic leukemia,
retinoids are being tested in clinical trials in several
tumor types [31]. Vitamin A metabolite, retinoic acid
(RA) transduces its signals by binding to specific nuclear
hormone receptors termed retinoic acid receptors (RAR),
which include RAR α, β, and γ [32]. These receptors
exist as predominately RAR/RXR heterodimers and to a
lesser extent RXR/RXR homodimer [33,34]. RARs bind
to all-trans-RA (ATRA) or 9-cis-retinoic acid, whereas
RXRs bind specifically to 9-cis-retinoic acid. The ligand-
receptor complex acts as a transcription factor whichbinds to a specific DNA sequence element found on
the promoter regions of target genes called retinoic
acid response element (RARE) [32-35]. Transcriptional
activation of RARs leads to differentiation and growth
arrest [36,37], as well as apoptosis [38-41], establishing
a prominent role of its use in anti-cancer therapy [31].
Interestingly, RA has an alternative function and in
some tissues RA promotes cell growth [41-46], and
paradoxically facilitates tumor development. It has been
well established that RA translates its pro-carcinogenic
properties in a RAR-independent mechanism through
activation of the nuclear receptor, peroxisome proliferator-
activated receptor β/δ (PPARβ/δ) and its target genes
[41,42]. Studies have shown that fatty-acid binding
protein 5 (FABP5) facilitates the transfer of ligands
from the cytoplasm to PPARβ/δ, which enhances PPARβ/
δ target genes that are directly involved in proliferative
responses and cell survival, promoting cell growth and
protection against apoptosis [47,48]. PPARβ/δ has been
implicated in the growth of other human cancers,
including lung carcinoma, breast cancer and colon can-
cer [49]. This nuclear receptor is well known to regu-
late the expression of angiogenic factor, vascular
endothelial growth factor A (VEGF-A), pro-survival
signals of PDK1/Akt, and anti-apoptotic protein, 14-3-
3epsilon [41,42,50].
The importance of FABP5 as a prognostic marker in
breast cancer patients was studied in a cohort of breast
tissues, pinpointing that elevated levels of FABP5 was
correlated with tumor grade and poor prognosis [51]. Not
only are elevated levels of FABP5 a key determinant in the
tumorigenic properties of mammary carcinoma [52], but
also pancreatic cancer cell subtypes with elevated levels of
FABP5 were associated with migration and invasion of
cells, paralleling to lack of tumor growth inhibition [53].
High FABP5 protein expression was evident in short term
glioblastoma survivors with highly proliferating tumors
compared to long term glioblastoma survivors [54]. In
light of the mounting evidence on the role of FABP5 in
cancer cell lines, FABP5 may serve as a novel prognostic
marker and inhibiting FABP5 can serve as a potential
combinatorial treatment to sensitize mammary carcinoma
cells to retinoid therapy.
In this study, we report that curcumin blocks cell pro-
liferation in RA-resistant TNBC cell lines by inhibiting
FABP5. It sensitizes these cells to RA mediated growth
suppression. The effect of curcumin in enhancing the
inhibitory effects of RA in TNBC cells is the result of
diminished expression of FABP5 and PPARβ/δ. Further-
more, we have identified a possible mechanism responsible
for growth suppression by curcumin and RA. Under-
standing the mechanisms by which curcumin reverses the
resistance of breast cancer to RA may provide alternate
treatments for RA-resistant TNBC patients.
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Reagents
As previously described [55,56], antibodies against FABP5
were obtained from R & D systems and β-tubulin was
purchased from Sigma Aldrich Co (St. Louis, MO).
Antibodies for PPARβ/δ and p65 were obtained from
Santa Cruz (Santa Cruz, CA) and Cell Signaling (Boston,
MA), respectively. Use of PPARβ/δ and p65 antibodies
was referenced in [57,58], respectively. Antibody against
β-actin was purchased from Cell Signaling (Boston, MA).
Anti-mouse and anti-rabbit immunoglobulin horseradish
peroxidase-conjugated antibodies were from BioRad,
and anti-goat immunoglobulin was from Santa Cruz.
Curcumin (C-1386) and all-trans-retinoic acid (R-2625)
were obtained from Sigma. MTT reagent (3-(4, 5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was
purchased from Sigma.
Cells
MDA-MB-231, MDA-MB-468, SkBr3 and MCF-7 cells
were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) and antibiotics. MDA-MB-468 was purchased from
American Type Culture Collection (Manassas, VA).
RA and Curcumin Preparation
A small amount of all-trans-RA was added to a 1 mL ali-
quot of 100% ethanol in the dark and rotated for 45 minutes
at 4°C. The absorbance of RA was measured at 350 nm
and the extinction coefficient of RA (ε = 45,300 M−1 cm−1)
was used to calculate the concentration of RA. A Stock of
1 mM was prepared and used for treatment of cells.
Curcumin was freshly prepared each time at a stock
concentration of 50 mM in dimethyl sulfoxide (DMSO)
and diluted at the appropriate concentration for treatment
of cells.
Western blots
Cells were cultured in 100 mm plates and treated with
DMSO or curcumin for 24 hours. Cells were lysed in a
buffer containing 150 mM NaCl, 10 mM Tris, pH 7.2,
0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM
EDTA, and 1 mM PMSF. Cells were lysed on ice for
1 hour and protein concentration was determined by the
Bradford Assay. Cell lysate was resolved by SDS-PAGE and
probed using the appropriate antibody. Anti-β-tubulin or
anti-β-actin was used for loading control.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
Cells were treated with curcumin and/or ATRA, and
RNA was extracted using Trizol (Life Technologies,
Grand, Island, NY). As described in the high capacity
RNA to cDNA kit from Applied Biosystems (Gaitherburg,MD), 2 μg total RNA was reverse transcribed into cDNA.
To determine expression of FABP5, PPARβ/δ and PDK1,
and VEGF-A, qRT-PCR was carried out by using commer-
cially available Taqman Chemistry and Assay on Demand
Probes (Applied Biosystems). GAPDH was used for
normalization. Detection and data analysis were carried
out on the ABI Step One Plus Real-Time PCR System.siRNA knockdown experiments
NF-κB p65 siRNA was purchased from Santa Cruz
Biotechnology. Briefly, 2 × 10 5 MDA-MB-231 cells were
plated in 6-well plates and transfected with 1 μg of p65
siRNA or control siRNA oligos using lipofectamine 2000 as
per the manufacturer’s instructions. Cells were incubated
for 24 hours after which cells were harvested and analyzed
for p65 and FABP5 expression using Western blot analysis.Cell Proliferation MTT Assay
MDA-MB-231 and MDA-MB-468 cells (2500 cells/well)
were seeded in a 96 well plate with Dulbecco’s modified
Eagle’s medium, 10% charcoal treated FBS and supple-
mented with antibiotics, and allowed to adhere over-
night. Cells were then treated with 30 uM curcumin
and/or 1 uM ATRA for 48 hours. Controls were treated
with 0.1% DMSO, 0.1% ethanol and/or the combination
of both. After 48 hours, 5 μg/ml MTT reagent (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide)
was added directly to the cells for 3 hours, or until crystals
formed. The media was carefully removed from the
plate, leaving the cells intact and the cells were then
resuspended in 150 μl of 0.04 M HCl in isopropanol.
Absorbance was read at 570 nm to determine cell
proliferation.BrdU (5-bromo-2’-deoxyuridine) cell proliferation assay
Cell Proliferation was also measured by the incorporation
of BrdU in cells by using the BrdU cell proliferation kit
from Cell Signaling. MDA-MB-231 cells were plated in
96-well plates and treated with 30 uM curcumin and/or 1
uM ATRA for 48 hours. Controls were treated with 0.1%
DMSO, 0.1% ethanol and/or the combination of both.
Cells were then pulsed with BrdU overnight, fixed and
followed by immunodetection of the incorporation of
BrdU label. Absorbance was read at 450 nm to determine
cell proliferation.Statistical analysis
Statistical significance of differences between treatments
was determined using two tailed student t-test and p values
were noted. Differences between groups were considered
statistically significant at p < 0.05.
Thulasiraman et al. BMC Cancer 2014, 14:724 Page 4 of 14
http://www.biomedcentral.com/1471-2407/14/724Results
Curcumin and ATRA suppress growth of RA-resistant
TNBC cell lines
To examine the effect of curcumin and ATRA on cell
viability, MTT assay was performed in two RA-resistant
TNBC cell lines. Mammary carcinoma cell, MDA-MB-231
is sensitive to curcumin [59] and resistant to ATRA [60].
As shown in Figure 1A, curcumin suppresses mammary
carcinoma cell growth of MDA-MB-231 cells in a dose
dependent manner (Figure 1A). By 48 hours, 30 μM
curcumin alone had produced a growth inhibitory effect
of approximately 40% in MDA-MB-231 cells. As illus-
trated in Figure 1B, the response to 30 μM of curcumin to
suppress cell proliferation of MDA-MB-231 cells is also
time dependent (Figure 1B). Thus, the proliferation of
MDA-MB-231 cells was inhibited by curcumin in a dose
and time-dependent manner. To assess whether curcumin
could sensitize these cells to RA-mediated growth sup-
pression, we performed MTT assay in MDA-MB-231 cells
treated with varying doses of curcumin in the presence or
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Figure 1 Curcumin sensitizes MDA-MB-231 cells to RA-mediated grow
dose of curcumin for 48 hours. Control was DMSO. The % cell proliferation fo
was calculated with respect to the treatment with DMSO. Data are mean of ±
(B) MDA-MD-231 cells were treated with 30 μM curcumin for varying time. Co
curcumin for the designated time was calculated with respect to the treatme
*p = 0.0025 versus control, **p = 0.002 versus control, ***p = 0.0007 versus co
20 μM curcumin and the combination of both agents for 48 hours. Control w
each of the treatment (curcumin, ATRA or both) was calculated relative to
The controls were set at 100%. Data are mean of ± SE (n = 3). (D) MDA-M
30 μM curcumin and 1 μM ATRA for 48 hours. Control was DMSO, ethanol or
(curcumin, ATRA or both) was calculated relative to their solvent, DMSO, etha
Data are mean of ± SE (n = 4). *p = 0.000036 versus curcumin treatment.treated only with ATRA were resistant to cell growth sup-
pression while 10 μM or 20 μM curcumin suppressed
growth, although not statistically significant (Figure 1C).
The combination of ATRA with 10 μM or 20 μM of
curcumin did not effect cell growth (Figure 1C). In fact,
cell growth of MDA-MB-231 cells treated with curcumin
and ATRA was similar to ATRA-treated cells, suggesting
that the proliferative function of RA suppresses the anti-
proliferative effects of curcumin. As expected, 30 μM cur-
cumin suppressed mammary carcinoma cell growth by 40%
(Figure 1d) and interestingly, MDA-MB-231 cells treated
with a combination of 30 μM curcumin and 1 μM ATRA
further reduced cell growth to approximately 60%, sensitiz-
ing TNBC MDA-MB-231 cells to the inhibitory effects of
RA (Figure 1d). At a maximal dose of 30 μM curcumin, this
agent was able to sensitize MDA-MB-231 cells to RA.
To test whether sensitivity to ATRA can be attained
by treatment of another RA-resistant breast cancer cells
with curcumin, we performed cell proliferation assay in
TNBC MDA-MB-468 cells. The growth inhibitory effect of
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ntrol. (C) MDA-MB-231 cells were treated with 1 μM ATRA (RA), 10 μM or
as DMSO, ethanol or a combination of both. The % cell proliferation for
their solvent, DMSO, ethanol or DMSO and ethanol, respectively.
B-231 cells were treated with 1 μM ATRA, 30 μM curcumin, or
a combination of both. The % cell proliferation for each of the treatment
nol or DMSO and ethanol, respectively. The controls were set at 100%.



































































Figure 2 RA-resistant MDA-MB-468 cells are sensitized to ATRA
by curcumin. (A) MDA-MD-468 cells were plated in 96 well plates,
treated with varying dose of curcumin for 48 hours and the control
used was DMSO. The % cell proliferation for each of the treatment
with curcumin for the designated concentration was calculated with
respect to the treatment with DMSO for the corresponding dose. Data
are mean of ± SE (n = 3). * p = 0.04 versus control, ** p = 0.04 versus
control, # p = 0.02 versus control, # # p = 0.008. (B) MDA-MD-468 cells
were plated in 96 well plates, treated with 30 μM curcumin for varying
time. The control was DMSO treated according to the timeframe of the
cells treated with curcumin. The % cell proliferation for each of the
treatment with curcumin for the designated time was calculated with
respect to the treatment with DMSO for the corresponding time. Data
are mean of ± SE (n = 3). * p = 0.009 versus control, ** p = 0.009 versus
control. (C) MDA-MB-468 cells (2500 cells/well) were plated in 96 well
plates, treated with 1 μM ATRA (RA), 30 μM curcumin (C), or 30 μM
curcumin and 1 μM ATRA for 48 hours. The control was DMSO, ethanol
or a combination of both. The % cell proliferation for each of the treat-
ment (curcumin, ATRA or both) was calculated relative to their solvent,
DMSO, ethanol or DMSO and ethanol, respectively. The controls were
set at 100%. Data are mean of ± SE (n = 4). * p = 0.03 versus curcumin.
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these cells in a time dependent manner (Figure 2b).
Similar to the inhibitory effects of 30 μM curcumin and
1 μM ATRA in MDA-MB-231 cells (Figure 1d), we also
observed similar results in MDA-MB-468. Curcumin
reduced growth of MDA-MB-468, while no such inhib-
ition was observed in the presence of ATRA (Figure 2c).
However, the combination of both 1 μM ATRA and
30 μM curcumin reduced growth of MDA-MB-468 when
compared to either treatment alone (Figure 2c). Thus,
curcumin sensitizes RA-resistant TNBC cells to the growth
suppressive effects of RA.
Curcumin down-regulates FABP5 and PPARβ/δ expression
level in MDA-MB-231 and MDA-MB-468
Sensitivity to RA is dependent on the expression level of
FABP5 in mammary carcinoma cells [41,42,51,52]. We
examined the expression level of FABP5 in RA-resistant
TNBC cell lines (MDA-MB-231 and MDA-MB-468) in
comparison to mammary carcinoma cells sensitive to
RA-mediated growth suppression. High mRNA expression
level of FABP5 was evident in the highly aggressive,
RA-resistant TNBC cell lines (Figure 3a), MDA-MB-231
and MDA-MB-468, which are both ER- and HER2- in
comparison to MCF-7 (ER+/HER2-) and SkBr3 (ER-/
HER2+). Similarly, there is high FABP5 protein expression
in MDA-MB-231 and MDA-MB-468 cell lines compared
to MCF-7 and SkBr3 cells (Figure 3b). Although SkBr3
mammary carcinoma cells are aggressive and HER2+,
these cells are sensitive to retinoic acid [61,62], as is MCF-
7 cells. It has been well established that FABP5 suppresses
sensitivity of cancer cells to retinoic acid [41,51], and the
fact that there is low expression level of FABP5 in SkBr3














































Figure 3 Expression levels of FABP5 and PPARβ/δ in breast
cancer cell lines. (A) Basal expression level of FABP5 was analyzed
by qRT-PCR in several breast cancer cell lines. GAPDH was used for
normalization. Data are mean of ± SE (n = 3). (B) Basal expression level
of FABP5 was analyzed by immunoblotting in several breast cancer cell
lines. β-tubulin was used as a loading control (C) Basal expression level
of PPARβ/δ was analyzed by qRT-PCR in several breast cancer cell lines.
GAPDH was used for normalization. Data are mean of ± SE (n = 3).
(D) Basal expression level of PPARβ/δ was analyzed by immunoblotting
in several breast cancer cell lines. β-actin was used as a loading control.
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of FABP5 and the lack of sensitivity to retinoic acid, and
not the aggressiveness of the cancer.
The mRNA and protein expression of the nuclear
receptor, PPARβ/δ which binds to ligands delivered by
FABP5 was also examined in the various breast cancer
cell lines. High mRNA and protein expression level ofPPARβ/δ was evident in the RA-resistant mammary car-
cinoma cells, MDA-MB-231 and MDA-MB-468 (Figure 3c
and d) when compared to MCF-7 cells. However, the
highly aggressive SkBr3 had low levels of PPARβ/δ
mRNA expression and undetectable levels of PPARβ/δ
protein expression (Figure 3c and d). This suggests there
is no correlation between the level of PPARβ/δ and the
aggressiveness of the breast cancer cells, but instead an
association between RA-resistance and high expression
of PPARβ/δ.
As shown in Figure 1d, 30 μM of curcumin suppressed
RA- resistant MDA-MB-231 cells, while the combination
with 1 μM RA sensitized these cells to respond to retinoic
acid-mediated growth suppression. To determine whether
the enhanced growth-inhibitory effects of curcumin
and RA on mammary carcinoma cells were likely due
to associated changes of FABP5 expression, we sought
to assess the effect of curcumin on FABP5 expression
in MDA-MB-231 cells. To investigate whether curcumin
regulates the expression level of FABP5, MDA-MB-231
cells were treated with varying concentrations of curcumin
for 24 hours, and the levels of FABP5 protein were deter-
mined by Western blot analysis. Protein levels of FABP5
were reduced dose-dependently in MDA-MB-231 cells
after treatment with curcumin (Figure 4a). A significant
decrease in FABP5 protein expression was evident at
30 μM curcumin (Figure 4a). The levels of FABP5 at
mRNA level were also analyzed by qRT-PCR. To analyze
the mRNA expression level of FABP5, MDA-MB-231 cells
were treated with 30 μM curcumin, mRNA isolated and
consistent with reduced protein expression (Figure 4a),
30 μM curcumin suppressed mRNA expression levels of
FABP5 by approximately 30% (Figure 4b). At 30 μM curcu-
min, FABP5 expression was reduced in MDA-MB-231 cells
(Figure 4a, b), and at the same dose, curcumin sensitized
them to RA-mediated growth suppression (Figure 1d).
It is known that FABP5 delivers ligands, such as RA, to
the nuclear receptor PPARβ/δ [47, 48], known to target
genes involved in cell survival and proliferation. Since cur-
cumin downregulates the expression of FABP5 (Figure 4a
and b), we investigated the effect of curcumin on PPARβ/
δ. MDA-MB-231 cells were treated with varying doses
of curcumin and at 30 μM of curcumin, a statistically
significant decrease in PPARβ/δ protein expression level
was observed (Figure 4c), concomitant to the decrease of
FABP5 expression by curcumin (Figure 4a and b). Sup-
pression of PPARβ/δ protein expression by curcumin was
dose-dependent (Figure 4c). Since 30 μM curcumin inhib-
ited PPARβ/δ protein expression, we also examined
PPARβ/δ mRNA expression at this concentration. Our
data shows that 30 μM of curcumin reduced PPARβ/δ
mRNA in these cells (Figure 4d). Because curcumin
affects the expression level of FABP5 and PPARβ/δ in















































































Figure 4 Curcumin suppresses the expression level of FABP5 and PPARβ/δ in MDA-MB-231 cells. (A) MDA-MB-231 cells were treated with
varying concentration of curcumin for 24 hours (0.1% DMSO was used for the control) prior to cell lysis. Cell lysates were resolved with SDS-PAGE and
immunoblotted with antibodies recognizing FABP5, and β-tubulin was used as a loading control (top panel). Bottom panel: Densitometry analyses
provide the relative amount of FABP5 normalized to β-tubulin. The analysis was performed in triplicates as mean of ± SE. +, p = 0.04 versus control, + +,
p = 0.03 versus control. (B) Total RNA was collected from MDA-MB-231 cells treated with curcumin (30 μM) for 4 hours or 0.1% DMSO as control.
Expression level of FABP5 was analyzed by qRT-PCR. GAPDH was used for normalization. Data are mean of ± SE (n = 3). * p = 0.0002 versus control
treatment (C) MDA-MB-231 cells were treated with varying concentration of curcumin for 24 hours (0.1% DMSO was used for the control) prior to cell
lysis. Cell lysates were resolved with SDS-PAGE and immunoblotted with antibodies recognizing PPARβ/δ, and β-actin was used as a loading control
(top panel). Bottom panel: Densitometry analyses provide the relative amount of PPARβ/δ normalized to β-actin. The analysis was performed
in triplicates as mean of ± SE. +, p = 0.04 versus control, + +, p = 0.02 versus control (D) Total RNA was collected from MDA-MB-231 cells
treated with curcumin (30 μM) for 4 hours or 0.1% DMSO as control. Expression level of PPARβ/δ was analyzed by qRT-PCR. GAPDH was used
for normalization. Data are mean of ± SE (n = 3)** p = 0.0003 versus control treatment.
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genes in RA-resistant MDA-MB-468 cells. Curcumin
reduced FABP5 protein expression in MDA-MB-468
cells in a dose dependent manner (Figure 5a), with a
statistically significant reduction at 30 μM of curcumin.
Consistently, FABP5 mRNA expression was also reduced
by 30 μM of curcumin (Figure 5b). To examine the effect
of curcumin on PPARβ/δ expression, we performed im-
munoblotting and qRT-PCR to determine the protein
and mRNA expression of PPARβ/δ, respectively. Curcu-
min suppressed PPARβ/δ protein expression in a dose-
dependent manner, with a statistically significant effect at
30 μM of curcumin treatment (Figure 5c). Comparable
results at the mRNA level of PPARβ/δ was also observed,
wherein curcumin suppressed PPARβ/δ mRNA expres-
sion levels in MDA-MB-468 cells (Figure 5d).
Regulation of FABP5 by curcumin is mediated by NF-κB
One of the established biological effects of curcumin to
its chemopreventive activity is the inhibition of the NF-κB pathway [27]. Constitutive NF-κB activity is associ-
ated with enhanced proliferation and survival of malig-
nant cells [63]. We sought to investigate whether the
effect of curcumin on the expression level of FABP5
depends on NF-κB, in particular since it has been
described that this transcription factor regulates FABP5
through the two putative NF-κB response elements on
the FABP5 promoter [56]. We assessed whether suppres-
sion of NF-κB by curcumin regulates the expression
level of FABP5 in MDA-MB-231 cells. Equal amounts of
cell lysates from control and 30 μM curcumin-treated
MDA-MB-231 cells were probed for the NF-κB subunit,
p65 using western blot analysis. As reported previously
[64] and as shown in Figure 6a, 30 μM curcumin de-
creased p65 protein expression in MDA-MB-231 cells. To
directly test the role of NF-κB to regulate FABP5 in
MDA-MB-231 cells, we used pyrrolidine dithiocarbamate
(PDTC), a chemical inhibitor on the activation of NF-κB,
to decrease p65 expression [65] and examined the effect
















































































Figure 5 Curcumin suppresses the expression level of FABP5 and PPARβ/δ in MDA-MB-468 cells. (A) MDA-MB-468 cells were treated with
30 μM of curcumin for 24 hours (0.1% DMSO was used for the control) prior to cell lysis. Cell lysates were resolved with SDS-PAGE and immunoblotted
with antibodies recognizing FABP5, and β-tubulin was used as a loading control. Bottom panel: Densitometry analyses provide the relative amount of
FABP5 normalized to β-tubulin. The analysis was performed in triplicates as mean of ± SE. +, p = 0.02 versus control, + +, p = 0.04 versus control (B)
Total RNA was collected from MDA-MB-468 cells treated with curcumin (30 μM) for 4 hours or 0.1% DMSO as control. Expression level of FABP5 was
analyzed by qRT-PCR. GAPDH was used for normalization. Data are mean of ± SE (n = 3). * p = 0.03 versus control treatment. (C) MDA-MB-468
cells were treated with varying concentration of curcumin for 24 hours (0.1% DMSO was used for the control) prior to cell lysis. Cell lysates
were resolved with SDS-PAGE and immunoblotted with antibodies recognizing PPARβ/δ, and β-actin was used as a loading control (top
panel). Bottom panel: Densitometry analyses provide the relative amount of PPARβ/δ normalized to β-actin. The analysis was performed in
triplicates as mean of ± SE. +, p = 0.04 versus control, + +, p = 0.007 versus control. (D) Total RNA was collected from MDA-MB-468 cells treated
with curcumin (30 μM) for 4 hours or 0.1% DMSO as control. Expression level of PPARβ/δ was analyzed by qRT-PCR. GAPDH was used for
normalization. Data are mean of ± SE (n = 3)** p = 0.03 versus control treatment.
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http://www.biomedcentral.com/1471-2407/14/724cells with 25 μM PDTC suppressed p65 expression level
at a modest level (Figure 6b). Concomitantly, we examined
the protein expression level of FABP5 in MDA-MB-231
cells treated with PDTC and observed that suppression
of the p65 subunit of NF-κB reduced FABP5 expression
in MDA-MB-231 cells (Figure 6b). In addition, p65 was
silenced in MDA-MB-231 cells and we examined the
protein expression of FABP5 (Figure 6c). Knock-down
of p65 suppressed FABP5 expression in these cells
(Figure 6c). These results support our hypothesis that
treatment with curcumin blocks the expression of NF-
κB regulated FABP5 gene expression, and that NF-κB is
a regulator in the molecular mechanism of curcumin
mediated suppression of FABP5.
Inhibition of PPARβ/δ target gene by curcumin and ATRA
We assessed the population of cells using BrdU incorpor-
ation assay upon treatment with curcumin and/or ATRA
in MDA-MB-231 cells. Mammary carcinoma cells were
treated with either curcumin, ATRA or the combinationof both agents for 48 hours and labeled with 5-bromo-
2-deoxyuridine (BrdU) overnight prior to analysis. As
expected, treatment of MDA-MB-231 cells with ATRA
did not reduce cell proliferation (Figure 7a). However,
MDA-MB-231-treated with curcumin showed a reduction
in the population of cells, noted by the reduction in BrdU
incorporation, and the effect was pronounced when
combined with ATRA (Figure 7a). Hence, curcumin
and RA together suppress cell proliferation, supporting
the results of the MTT assay (Figure 1d).
Activation of PPARβ/δ induces the transcriptional activ-
ity of several downstream genes in mammary carcinoma
cells such as the survival factor PDK1/Akt, VEGF-A and
14-3-3-epsilon [41,42,50]. We examined the effect of
curcumin and/or ATRA on the mRNA expression level of
PDK1 in MDA-MB-231. As shown in Figure 7b, a 4-hour
treatment of MDA-MB-231 cells with 1 μM of ATRA
enhanced the mRNA level of the survival factor, PDK1.
Although RA enhanced survival factor, PDK1 mRNA
expression within 4 hours, enhanced cell proliferation
FABP5
p65
PDTC        - +
p65
β - tubulin





















Figure 6 Curcumin regulates FABP5 via NF-κB. (A) MDA-MB-231
cells were treated with 30 μM curcumin, total protein extracted
and probed for p65. β-tubulin was used as a loading control (B)
MDA-MB-231 cells were treated with 25 μM PDTC, cell lysates were
resolved with SDS-PAGE and immunoblotted with antibodies
recognizing p65 or FABP5. β-tubulin was used as a loading control.
(C) MDA-MB-231 cells were transfected with control and p65 siRNA for
24 hours, protein extracted and expression level of p65 and FABP5 was
examined by immunoblotting with antibodies recognizing p65 and
FABP5, respectively. β-tubulin was used as a loading control.
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http://www.biomedcentral.com/1471-2407/14/724was not observed after 48 hours of treatment with RA
and growth of the cells remained as that of the control
cells (Figure 7a). The conventional growth inhibitoryproperties of RA in some cells [35,37-40,66] was not
observed in triple negative breast cancer cell line,
MDA-MB-231 but as noted previously [60] and as seen
in Figures 1d and 7a, MDA-MB-231 cells are retinoic acid
resistant. However in some carcinomas, RA enhances
hyperproliferation [41,67-69]. To determine whether there
is delayed response to hyperproliferation and PDK1
expression, MDA-MB-231were treated with 1 μM ATRA
for 2–8 days. At approximately 6 days, RA promoted
hyperproliferation of MDA-MB-231 cells (Figure 7c). The
timeframe at which PDK1 is induced does not correlate
with the time at which MDA-MB-231 cells responds to
RA with hyperproliferation, but these results demonstrate
that these cells are resistant to the growth inhibitory ef-
fects of RA and thus RA-resistant. While ATRA enhanced
PDK1 expression, a small reduction (~20%) in mRNA
levels was observed when cells were treated with curcu-
min, though the effect was not statistically significant
(Figure 7b). PPARβ/δ ligands have been shown to activate
PDK1 expression in several cells [41,42] but other reports
suggest that PDK1 is not a direct target of PPARβ/δ
[70,71]. In our study, we observed that despite the down-
regulation of PPARβ/δ by curcumin in MDA-MB-231
cells (Figure 4c, d), curcumin does not suppress PDK1
(Figure 7b), suggesting that PDK1 is not regulated by
PPARβ/δ in these cells (Figure 7b). However, the combin-
ation of curcumin and ATRA further reduced PDK1 at
the mRNA level, compared to curcumin alone (Figure 7b).
Although PDK1 may not be a PPARβ/δ target gene in
these cells, we can conclude that RA regulates PDK1
mRNA expression by an alternative mechanism in these
cells. Curcumin may regulate this mechanism and sup-
press the upregulation of PDK1 mRNA expression by RA.
Due to the controversy that remains on whether PDK1
is a direct target of PPARβ/δ, we also examined the
effect of curcumin and RA on another PPARβ/δ target
gene, VEGF-A [72]. As shown in Figure 7d, ATRA induced
VEGF-A mRNA expression, while curcumin suppressed
VEGF-A (Figure 7d). In addition, the combination of cur-
cumin and RA further suppressed VEGF-A expression
(Figure 7d). Curcumin-mediated suppression of PPARβ/δ
in MDA-MB-231 cells, when compared to control, reduces
the downstream target gene, VEGF-A by approximately
40%, while curcumin suppressed RA-mediated transcrip-
tional activity of PPARβ/δ target gene, VEGF-A by an add-
itional 30%. This suggests that the proliferative effect of
RA in these cells is diminished in the combination with
curcumin, owing to the fact that curcumin suppresses the
FABP5/PPARβ/δ pathway, and MDA-MB-231 cells are
sensitized to the growth inhibitory effects of RA.
Discussion
In this study, we show that curcumin sensitizes RA-
resistant TNBC cells to RA-mediated growth suppression
AC























































































Figure 7 Curcumin and ATRA reduce VEGF-A expression in MDA-MB-231 cells. (A) MDA-MB-231 cells were plated in 96 well plates treated
with 1 μM ATRA (RA), 30 μM curcumin (C) or 30 μM curcumin and 1 μM ATRA for 48 hours. The control was DMSO, ethanol or a combination of both.
The % BrdU incorporation for each of the treatment (curcumin, ATRA or both) was calculated relative to their solvent, DMSO, ethanol or DMSO and
ethanol, respectively. Data are mean of ± SE (n = 3). *, p = 0.035 versus curcumin. (B) MDA-MB-231 cells were treated with 30 μM curcumin (C) for
24 hours prior to the addition of 1 μM ATRA (RA) for 4 hours. Total RNA was collected from MDA-MB-231, qRT-PCR was performed and expression
levels of PDK1 were measured. GAPDH was used for normalization. Data are mean of ± SE (n = 3). *, p = 0.012 versus curcumin. (C) MDA-MB-231 cells
were plated in 96 well plates treated with 1 μM ATRA for 2–8 days. The % BrdU incorporation for each of the treatment was calculated relative to their
solvent, DMSO. Data are mean of ± SE (n = 3). *, p = 0.0008 versus control ** p = 0.002 versus control. (D) MDA-MB-231 cells were treated with 30 μM
curcumin (C) for 24 hours prior to the addition of 1 μM ATRA (RA) for 4 hours. Total RNA was collected from MDA-MB-231, qRT-PCR was performed
and expression levels of VEGF-A was measured. GAPDH was used for normalization. Data are mean of ± SE (n = 3). +, p = 0.016 versus control, ++,
p = 0.03 versus curcumin.
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δ pathway. The high expression level of FABP5 in the
aggressive RA-resistant TNBC cells, MDA-MB-231 and
MDA-MB-468, correlates with the marked upregulation
of FABP5 observed in human breast tumors, particularly
in tumors categorized by its invasive properties as well
as late stages of breast cancer [51,52]. Our observation
shows that curcumin downregulates FABP5 expression,
and concomitantly suppresses its cognate receptor,
PPARβ/δ. Adding to the network of genes regulated by
curcumin [28], we demonstrate that curcumin regulates
the pro-proliferative gene, FABP5 and the nuclear recep-
tor, PPARβ/δ.
Several PPARβ/δ target genes, such as PDK1 and
VEGF-A are involved in proliferation and angiogenesis,
respectively [41,42,72]. In mammary carcinoma cells
expressing high levels of FABP5, FABP5 delivers RA to
PPARβ/δ, enhances the transcriptional activity of PPARβ/
δ and activates PPARβ/δ target gene, PDK1 and VEGF-A
[41,42]. Based on previous reports that RA regulates
PDK1 through PPARβ/δ, we also examined the regulation
of PDK1 by RA in MDA-MB-231 cells. From our data, weconclude that RA regulates PDK1, however regulation of
PDK1 by RA is not via PPARβ/δ in these cells. Several
studies have also demonstrated that PDK1 is not a
PPARβ/δ target gene [70,71]. Comparing the suppression
of PDK1 by curcumin and/or ATRA suggests that curcu-
min alone reduces PDK1 expression (not statistically
significant), while the combination of the agents further
suppress PDK1 mRNA expression. RA may be regulating
PDK1, at the mRNA level, by an alternative mechanism.
Hence, curcumin may regulate this mechanism and
thereby suppress RA-mediated upregulation of PDK1
mRNA. Further studies will be required to dissect the
pathway by which RA regulates PDK1 in these cells.
Examining the effect of curcumin and ATRA on another
PPARβ/δ target gene, VEGF-A, we discovered that RA
enhances VEGF-A, while curcumin significantly decreases
VEGF-A mRNA expression. Suppression of FABP5 by
curcumin reduces the delivery of RA to PPARβ/δ, result-
ing in diminished transcriptional activation of PPARβ/δ
by ATRA. Curcumin suppresses VEGF-A expression by
approximately 45%, however in the combination of ATRA,
mRNA expression of VEGF-A is reduced to an additional
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delivery of ATRA to PPARβ/δ, hence reducing RA-
mediated transcriptional activation of PPARβ/δ target
gene, VEGF-A.
Curcumin regulates multiple transcription factors,
including NF-κB. TNBC cells constitutively express NF-
κB, a transcription factor that regulates genes known to be
involved in proliferation, metastasis and angiogenesis [63].
Having shown previously that NF-κB regulates FABP5
[56], we demonstrate that the mechanism by which curcu-
min regulates FABP5 gene expression is mediated through
the suppression of NF-κB. Hence, FABP5 is regulated by
NF-κB in mammary carcinoma MDA-MB-231 cells and
curcumin downregulates FABP5 expression by suppress-
ing the p65 subunit of NF-κB.
Limited therapeutic options and poor prognosis of
TNBC patients after the treatment with standard con-
ventional drugs creates an emerging need to understand
the molecular basis of this disease, as well as to identify
alternative chemotherapeutic targets and treatments. A
correlation with RA resistance in breast cancer tumors
has been attributed to the high expression level of
FABP5 [41,42,52] which has been associated with poor
prognosis in cancer [51]. The fact that TNBC cell lines,
MDA-MB-231 and MDA-MB-468, express high levels of
FABP5 and are resistant to retinoid therapy suggests that
by suppressing the expression level of FABP5, these sub-
types of breast cancer cells can overcome RA resistance.
Interestingly, our data show that downregulation of the
FABP5/PPARβ/δ pathway by curcumin restores the
sensitivity of RA-resistant TNBC cells to the inhibitory
effects of RA and suppresses cell growth in the combin-
ation of curcumin and ATRA. Although a dose of 30 μM
curcumin is required to reduce cell growth of MDA-MB-
231 cells, it is at this dose that curcumin suppresses the
FABP5/PPARβ/δ pathway. Hence, combining ATRA with
30 μM curcumin reduces proliferation an additional 20%
and chemosensitizes TNBCs to retinoid therapy. A mar-
ginal decrease in cell proliferation by the combination of
curcumin and retinoic acid is consistent with the modest
suppression of the FABP5/PPARβ/δ pathway. As shown
in a previous study, that despite a modest reduction in
breast cancer cell proliferation, the combination of
metformin and hyperthermia translated to a significant
reduction in colony sphere formation [73]. Similarly,
synthetic analogues of curcumin, CDF reversed the resist-
ance of pancreatic cells to gemcitabine [74]. Although a
10-20% reduction in cell proliferation was observed in the
combination of the two drugs in comparison to CDF
alone, the growth inhibitory effects of the combined drugs
resulted in significant reduction in colony formation.
Despite the modest reduction in our study on mammary
carcinoma cell growth with the combination of curcumin
and ATRA, this study may translate to a more significanteffect in vivo. Future studies will explore the effect of
curcumin and retinoic acid on the transformational
properties of cancer cells to provide information for its
use in in vivo studies.
Breast cancer cells respond to curcumin at 1–50 μM
range with the strongest effect between 20–30 μM [15] .
Consistent with our data, several reports have docu-
mented that 30 μM curcumin suppresses MDA-MB-231
mammary carcinoma cell growth within the time frame of
48 hours by approximately 40-50% [59,75-77]. Curcumin
has also been studied in several cancer models such as
colorectal carcinoma, non small cell lung cancer and pan-
creatic cancer, and depending on the cancer model, the
IC50 of curcumin has not only varied among the different
cancers, but also between subtypes within a cancer model
[78]. One of the criteria that determines the degree to
which curcumin can suppress cell proliferation is
dependent on the uptake of curcumin within the cells.
For instance, MDA-MB-231 cells were more sensitive
to the anti-proliferative activity of 25–50 μM curcumin
compared to MCF-7 cells [79]. The cellular uptake of
curcuminoids in breast cancer cells correlated with the
inhibitory activity of this compound which is a determin-
ant of the IC50 of curcuminoids in the cancer subtype
[79]. Despite the differences in the IC50 among cancer
cells, one of the advantages of curcumin is its preferential
uptake by tumor cells compared to normal cells [80].
Among the strategies used to improve the efficacy of
curcumin and potentiate the growth-inhibitory activity
of this agent, and more importantly reversing chemore-
sistance in cancer models, has been aimed at designing
and synthesizing novel structural analogues of curcumin
[81]. One such compound is demethoxycurcumin which
has the potential of suppressing a wide range of mammary
carcinoma cell lines with the most efficient inhibitory
activity on TNBC (MDA-MB-231 and BT-20) [82]. Ana-
logues of curcumin, such as HO-3867 are taken up by
multiple drug resistant or sensitive cancer cell lines at
considerably lower doses than curcumin [83], while
synthetic analogues, G0-Y030, FLLL-11 and FLLL-12
promotes anti-proliferation in colorectal cancer cells at
lower IC50 than curcumin [81]. The safety and tolerance
of curcumin has been demonstrated in several clinical
trials [84], however the disadvantage of curcumin is its
poor absorption properties [22]. One such study has
shown the improvement in the reduction of cell growth
and colony formation of colon cancer stem cells upon
treatment with curcumin analog, CDF with 5-fluorouracil
and oxaliplatin compared to 5-FU and oxaliplatin with
free curcumin [85]. To prevent the emergence on the
chemoresistance of cancer cells to conventional chemo-
therapeutic agents, several studies have employed the
use of curcumin to sensitize cancer cells to chemother-
apeutic drugs, such as doxorubicin [86]. By improving
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cumin, curcumin derivatives may be more potent in
suppressing the FABP5/PPARβ/δ pathway, and enhance
the efficacy of RA by reducing the dosage to be used
in vivo, in order to better tolerate its use in cancer patients.
Mounting evidence has demonstrated that the expres-
sion level of FABP5 is low in low grade tumors and highly
upregulated as the progression of the disease manifests to
aggressive, metastatic tumors [51,52,87-89], clarifying the
importance of a rational drug design targeting FABP5.
Identifying potential drug targets against FABP5 will
establish the sensitivity of cancer cells to RA and may
prove to be a rationale to improve the clinical outcome of
RA use in breast cancer patients. Our studies demonstrate
that curcumin can be used to overcome RA resistance in
mammary carcinoma cells since curcumin suppresses
FABP5 expression level, reducing the delivery of RA to
PPARβ/δ and downregulating the expression of PPARβ/δ
target gene. To overcome the challenges of using free
curcumin, novel structural analogs of curcumin have
been synthesized to improve the chemotherapeutic effects
[22,23]. In addition, curcumin encapsulated in liposomes
or production of curcumin nanoparticles has been formu-
lated to enhance the selective delivery of these drugs
[90-92]. Using various derivatives of curcumin would
improve bioavailability which may improve treatment of
breast cancer with RA.
Taken together, we have shown that curcumin in com-
bination with RA sensitizes RA-resistant TNBC cells by
suppressing FABP5/PPARβ/δ pathway, and promotes
the growth inhibitory effect of RA. Knowing that the
acquired resistance to RA in TNBC cells is manifested
by the increased expression of FABP5, future studies will
entail the development of inhibitors against FABP5. More-
over, we provide evidence that curcumin can inhibit
FABP5 and the use of curcumin or its analogs may serve
as potential therapeutic agents to overcome RA resistance
in RA-resistant breast cancer cells.Conclusions
The results of this study showed that curcumin sensitizes
RA-resistant TNBC cells to RA-mediated growth suppres-
sion. By suppressing the expression level of FABP5 and
its cognate receptor, PPARβ/δ, curcumin suppresses the
downstream target gene of PPARβ/δ, VEGF-A. The
inhibitory effects of curcumin on the FABP5/PPARβ/δ
pathway reduce RA-induced VEGF-A expression. The
mechanism by which curcumin regulates FABP5 is by
downregulating the transcription factor, NF-κB. Further
investigation using analogs of curcumin or liposome
based curcumin should be employed to evaluate the
use of this drug to further enhance efficacy of RA and
promote RA sensitivity in RA-resistant breast cancers.Abbreviations
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